Skip to main content
Journal ArticleOPEN ACCESS

Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E

Clinical Case Reports (2021) 9(8)
DOI: 10.1002/ccr3.4713
1Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute exacerbations. We here describe its use in a woman with CF and respiratory failure.

Author supplied keywords

Cite

CITATION STYLE

APA

Salvatore, D., Colangelo, C., D’andria, M., Marsicovetere, G., & Passarella, D. (2021). Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E. Clinical Case Reports, 9(8). https://doi.org/10.1002/ccr3.4713

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free